Sanaria Inc.
Clinical trials sponsored by Sanaria Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New malaria vaccine trial aims to block infection without causing illness Results expected Sep 2026 (estimated)
- New malaria vaccine shows promise in african trial Results expected Feb 2027 (estimated)
-
New malaria vaccines show promise in protecting indonesian soldiers
Vaccine CompletedThis study tested two experimental malaria vaccines in 345 healthy Indonesian soldiers deployed to a malaria-endemic region. One vaccine uses weakened malaria parasites, and the other uses live parasites with a preventive drug. The goal was to see if either vaccine could safely p…
Phase 2 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
-
New malaria vaccine shows promise in first human trial
Vaccine CompletedThis study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Bu…
Phase 1 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:07 UTC